Volpara Health Technologies Ltd (ASX: VHT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Volpara Health Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $288.71 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 254.83 million
Earnings per share -0.036
Dividend per share N/A
Year To Date Return 2.71%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Volpara Health Technologies Ltd (ASX: VHT)
    Latest News

    Dollar sign made from grass growing from ground as one person drips water on it and another holds coin
    Growth Shares

    2 ASX shares I think are great long-term buys

    These two ASX shares have strong outlooks this decade. Here's why...

    Read more »

    ASX bank shares buy A young boy in a business suit giving thumbs up with piggy banks and coin piles
    Share Market News

    Could now be a great time to start investing in ASX shares?

    Is it a good time to start investing in ASX shares? There has been a lot of volatility in 2022.

    Read more »

    A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
    Earnings Results

    Volpara share price up on record full-year results

    ASX investors appear to be pleased with Volpara's results.

    Read more »

    A woman faces the camera with her lip raised up to the side in total confusion.
    Growth Shares

    2 ASX-listed companies that are growing rapidly

    These two ASX shares have dropped heavily, yet as companies they continue to grow.

    Read more »

    A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
    Growth Shares

    Buy these 2 impressive ASX shares in May 2022: experts

    These two ASX shares are both growing and could be impressive investments, according to experts.

    Read more »

    Two plants grow in jars filled with coins.
    Growth Shares

    2 rapidly growing ASX shares that are on sale: experts

    These two ASX shares could be at bargain prices despite their continuing growth.

    Read more »

    A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
    Healthcare Shares

    Volpara share price slips despite milestone CEO change

    Volpara shares have come under pressure despite the company's management update.

    Read more »

    ASX shares upgrade buy Woman in glasses writing on buy on board
    Growth Shares

    2 great ASX shares to buy in April: experts

    Temple & Webster is one ASX share rated as an opportunity.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    a happy investor with a wide smile points to a graph that shows an upward trending share price
    Growth Shares

    2 ASX growth shares to buy this month: experts

    Temple & Webster is one of the leading ASX growth shares that are rated as a buy.

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Broker Notes

    Down 33% in 2022, is this ASX healthcare share a buy following the company's latest trial result?

    What can be said about Volpara's prospects in 2022?

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    4 ASX healthcare shares at 52-week lows

    A number of ASX healthcare shares just hit 52-week lows.

    Read more »

    Frequently Asked Questions

    No, the ASX healthcare share has not yet paid any dividends.

    Volpara listed on 27 April 2016.

    VHT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Volpara Health Technologies Ltd

    Volpara Health Technologies Ltd (ASX: VHT) is a small but growing research, development, and manufacturing company that provides breast screening technology and risk analysis for patients and medical professionals.

    Volpara’s artificial intelligence-powered software for early detection of breast cancer is used by more than 2,000 facilities and more than 5,600 mammography technologists, impacting nearly 15 million patients globally. Volpara is based in Wellington, New Zealand, and also has a US office in Seattle.

    VHT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Mar 2024 $1.14 $0.00 0.00% 539,358 $1.13 $1.14 $1.13
    27 Mar 2024 $1.14 $0.00 0.00% 127,606 $1.13 $1.14 $1.13
    26 Mar 2024 $1.14 $0.00 0.00% 64,750 $1.13 $1.14 $1.13
    25 Mar 2024 $1.14 $0.01 0.88% 664,855 $1.13 $1.14 $1.13
    22 Mar 2024 $1.13 $-0.01 -0.88% 1,412,689 $1.13 $1.13 $1.13
    21 Mar 2024 $1.14 $0.01 0.89% 1,093,007 $1.13 $1.14 $1.13
    20 Mar 2024 $1.13 $0.00 0.00% 84,031 $1.13 $1.14 $1.13
    19 Mar 2024 $1.13 $0.00 0.00% 2,861,710 $1.13 $1.13 $1.13
    18 Mar 2024 $1.13 $0.00 0.00% 531,121 $1.13 $1.13 $1.13
    15 Mar 2024 $1.13 $0.00 0.00% 385,743 $1.13 $1.14 $1.13
    14 Mar 2024 $1.13 $0.00 0.00% 2,037,806 $1.13 $1.14 $1.13
    13 Mar 2024 $1.13 $0.00 0.00% 558,056 $1.13 $1.13 $1.13
    12 Mar 2024 $1.13 $0.00 0.00% 310,599 $1.12 $1.13 $1.12
    11 Mar 2024 $1.12 $0.00 0.00% 503,145 $1.12 $1.13 $1.12
    08 Mar 2024 $1.12 $0.00 0.00% 270,682 $1.13 $1.13 $1.12
    07 Mar 2024 $1.12 $-0.01 -0.88% 137,991 $1.13 $1.13 $1.12
    06 Mar 2024 $1.13 $0.01 0.89% 153,301 $1.12 $1.13 $1.12
    05 Mar 2024 $1.12 $0.00 0.00% 47,579 $1.12 $1.13 $1.12
    04 Mar 2024 $1.12 $0.00 0.00% 182,554 $1.12 $1.13 $1.12
    01 Mar 2024 $1.13 $0.00 0.00% 847,151 $1.13 $1.13 $1.12
    29 Feb 2024 $1.12 $0.00 0.00% 32,406 $1.12 $1.12 $1.12
    28 Feb 2024 $1.12 $0.00 0.00% 1,552,964 $1.12 $1.13 $1.12
    27 Feb 2024 $1.12 $0.00 0.00% 285,243 $1.12 $1.13 $1.12

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 Aug 2023 Mark Bouw Issued 450,000 $585,000
    Issue of options.
    02 Jun 2023 Teri Thomas Sell 3,577 $2,546
    On-market trade.
    01 Jun 2023 Teri Thomas Exercise 75,280 $57,213
    Conversion of securities. 150,561 RSUs, As per announcement on 02-06-2023
    01 Jun 2023 Teri Thomas Buy 75,280 $57,213
    Conversion of securities. As per announcement on 02-06-2023

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Roger Allen Non-Executive Director Jun 2010
    Roger was Volpara s first major investor, joined the Board
    prior to FDA approval in June 2010, and was Chair from
    October 2015 to March 2019.
    Roger is a well-known entrepreneur, venture capitalist (VC),
    and social impact investor and philanthropist whose global
    career has spanned over 50 years. He helped pioneer the
    Australian technology industry through the Computer
    Power Group, one of the first Australian-founded tech
    companies to scale globally and subsequently IPO in 1987,
    turning over approx. $1B in today s currency. Following
    the companys acquisition in 1995, he cofounded Allen &
    Buckeridge Pty Ltd, one of the first early-stage VC firms.
    Mr John Dimitrious Pavlidis Non-Executive Director Feb 2015
    John Pavlidis joined the VHT board in February
    2015 and has more than 30 years of experience
    as a senior healthcare executive, CEO, or
    company director in the areas of womens health,
    diagnostic imaging, image analysis and artificial
    intelligence, and cardiovascular therapies.
    Mr Paul Reid Non-Executive DirectorNon-Executive Chairman Mar 2018
    Paul joined the Board in March 2018 and brings extensive
    commercial experience gained across a range of
    technology/Software as a Service businesses.
    He was the founding CEO and Chairman of Figured
    Limited, a fintech SaaS company that provides
    management accounting software to farmers in the
    United States, the United Kingdom ,
    Australia, and New Zealand . Figured was the
    NZ Hi-Tech Startup Company of the Year in 2016 and
    has grown at an incredible pace, funded by private,
    corporate and venture capital (VC) investors.
    Ms Karin Lindgren Non-Executive Director Jan 2020
    Karin joined the Board in 2020. She brings over 35 years
    experience in health information technology as a senior
    technology executive and law firm partner. As one of
    the earliest healthcare technology lawyers in the USA,
    Karin has an in-depth knowledge of data governance,
    data privacy, SaaS, and US healthcare, and has extensive
    professional networks across the IT landscape
    Ms Ann Custin Non-Executive Director Sep 2021
    network of industry contacts from an extensive
    career in healthcare across Europe, the Americas,
    and Asia. Her most recent executive role was with
    Siemens Healthineers, where she served as both CFO
    and board director of Siemens Medical Solutions.
    Prior to this role, Ann served as Chief Operating
    and Financial Officer of Scientx and President &
    CEO of USA Draeger Medical Systems, Inc.
    Ms Teri Thomas Chief Executive OfficerManaging Director Apr 2022
    Teri joined the Board in October 2022. She has a
    long history of executive management in healthcare
    IT ranging from strategy and operations to running
    global sales and marketing teams. This includes a
    20-year career at Epic, a global leader in electronic
    health record (EHR) systems and other software
    solutions used by hospitals and healthcare
    organisations in the United States and internationally
    Mr Mark Bouw Non-Executive Director Jan 2023
    Mr Bouw is a experienced senior healthcare CEO .He is a visiting consultant at Stanford University Graduate Business School Seed Program in the United States and is a visiting mentor for Stanfords Ignite program.
    Mr Craig Hadfield Chief Financial OfficerJoint Company Secretary Mar 2017
    -
    Mr Fred Struve General CounselJoint Company Secretary Oct 2022
    -
    Craig Hadfield Chief Financial OfficerJoint Company Secretary
    -
    Fred Struve General CounselJoint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No Top 20 27,534,688 10.84%
    Patagorang Pty Ltd 18,467,848 7.27%
    Ralph Highnam And Kyc Trustees 106 Limited <Highnam Share A/C> 16,213,561 6.38%
    Citicorp Nominees Pty Limited 11,830,450 4.66%
    HSBC Custody Nominees (Australia) Limited 8,187,911 3.22%
    Custodial Services Limited <Beneficiaries Holding A/C> 8,154,911 3.21%
    Bnp Paribas Noms (Nz) Ltd <Drp> 7,061,556 2.78%
    Prof Sir Michael Brady 6,619,075 2.61%
    Mr Marcus Sarner 5,980,404 2.35%
    National Nominees Limited 4,728,818 1.86%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient 4,420,193 1.74%
    Sir Martin Francis Wood 3,004,655 1.18%
    Lady Kathleen Audrey Wood 3,004,654 1.18%
    BNP Paribas Noms Pty Ltd <Drp> 2,527,511 0.99%
    Prof Martin Yaffe 1,966,483 0.77%
    Mr John Anthony Dell 1,928,864 0.76%
    BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Limited 1,917,409 0.75%
    Prof Nico Karssemeijer 1,806,806 0.71%
    Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C> 1,519,964 0.60%
    RX HOUSE TRUST PTY LTD 880,758 0.35%

    Profile

    since

    Note